Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan P.; Hassel J.; Rutkowski P.; Baurain J.; Butler M.; Schlaak M.; Sullivan R.; Ochsenreither S.; Dummer R.; Kirkwood J.; Joshua A.; Sacco J.; Shoushtari A.; Orloff M.; Piulats J.; Milhem M.; Salama A.; Curti B.; Demidov L.; Gastaud L.; Mauch C.; Yushak M.; Carvajal R.; Hamid O.; Abdullah S.; Holland C.; Goodall H.; Piperno-Neumann S.

doi:10.1056/nejmoa2103485

← Today's brief

StudyUnblinded

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan P. et al. · The New England journal of medicine · Friday, January 1, 2021

Read original

n 378Funding Independent

The one catch: Unblinded, so outcome assessment may be swayed by knowing the assignment.

Source

Nathan P. et al.. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. The New England journal of medicine. Friday, January 1, 2021.
doi:10.1056/nejmoa2103485

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.